Nwam LLC Invests $18.61 Million in VanEck Biotech ETF $BBH

Nwam LLC acquired a new stake in VanEck Biotech ETF (NASDAQ:BBH) in the 2nd quarter, HoldingsChannel.com reports. The institutional investor acquired 91,586 shares of the company’s stock, valued at approximately $18,614,000. VanEck Biotech ETF makes up 0.9% of Nwam LLC’s holdings, making the stock its 20th largest position.

A number of other institutional investors have also modified their holdings of the stock. Northwestern Mutual Wealth Management Co. boosted its holdings in shares of VanEck Biotech ETF by 40,463.3% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 494,061 shares of the company’s stock valued at $93,506,000 after purchasing an additional 492,843 shares during the period. Quantitative Investment Management LLC bought a new stake in VanEck Biotech ETF during the 2nd quarter valued at $7,589,000. Ascent Advisors LLC purchased a new stake in shares of VanEck Biotech ETF in the 1st quarter worth $11,178,000. Raymond James Financial Inc. grew its position in shares of VanEck Biotech ETF by 245.9% during the 2nd quarter. Raymond James Financial Inc. now owns 67,940 shares of the company’s stock worth $10,414,000 after buying an additional 48,297 shares in the last quarter. Finally, Bank of America Corp DE increased its stake in shares of VanEck Biotech ETF by 44.3% during the first quarter. Bank of America Corp DE now owns 66,338 shares of the company’s stock valued at $12,473,000 after buying an additional 20,375 shares during the period. 32.05% of the stock is owned by hedge funds and other institutional investors.

VanEck Biotech ETF Stock Performance

BBH stock opened at $235.50 on Tuesday. VanEck Biotech ETF has a 1-year low of $160.91 and a 1-year high of $244.35. The business has a 50-day moving average price of $213.87 and a 200 day moving average price of $197.38.

Insider Activity at VanEck Biotech ETF

In other news, major shareholder Sardar Biglari sold 2,749 shares of the company’s stock in a transaction that occurred on Thursday, July 16th. The shares were sold at an average price of $16.70, for a total value of $45,908.30. Following the completion of the sale, the insider owned 3,549,961 shares of the company’s stock, valued at approximately $59,284,348.70. This represents a 0.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last three months, insiders have sold 10,493 shares of company stock valued at $175,335.

VanEck Biotech ETF Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.